Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 113

1.

Clinical features of patients with Philadelphia-negative myeloproliferative neoplasms complicated by portal hypertension.

Yan M, Geyer H, Mesa R, Atallah E, Callum J, Bartoszko J, Yee K, Maganti M, Wong F, Gupta V.

Clin Lymphoma Myeloma Leuk. 2015 Jan;15(1):e1-5. doi: 10.1016/j.clml.2014.04.004. Epub 2014 Jun 11.

2.

JAK2 V617F mutation status of 232 patients diagnosed with chronic myeloproliferative neoplasms.

Payzin KB, Savasoglu K, Alacacioglu I, Ozdemirkiran F, Mutlu BB, Bener S, Calli AO, Kucukzeybek BB, Aksun S.

Clin Lymphoma Myeloma Leuk. 2014 Dec;14(6):525-33. doi: 10.1016/j.clml.2014.02.013. Epub 2014 Mar 5.

PMID:
24811089
3.

The clinical significance of JAK2V617F mutation for Philadelphia-negative chronic myeloproliferative neoplasms in patients with splanchnic vein thrombosis.

Yonal I, Pinarbası B, Hindilerden F, Hancer VS, Nalcaci M, Kaymakoglu S, Diz-Kucukkaya R.

J Thromb Thrombolysis. 2012 Oct;34(3):388-96.

PMID:
22569900
4.

[Significance of the JAK2V617F mutation in patients with chronic myeloproliferative neoplasia].

Iványi JL, Marton E, Plander M.

Orv Hetil. 2011 Nov 6;152(45):1795-803. doi: 10.1556/OH.2011.29226. Hungarian.

PMID:
22011365
5.

Association between thromboembolic events and the JAK2 V617F mutation in myeloproliferative neoplasms.

Takata Y, Seki R, Kanajii T, Nohara M, Koteda S, Kawaguchi K, Nomura K, Nakamura T, Morishige S, Oku E, Osaki K, Hashiguchi E, Mouri F, Yoshimoto K, Nagafuji K, Okamura T.

Kurume Med J. 2014;60(3-4):89-97. Epub 2014 May 26.

6.

Changing concepts of diagnostic criteria of myeloproliferative disorders and the molecular etiology and classification of myeloproliferative neoplasms: from Dameshek 1950 to Vainchenker 2005 and beyond.

Michiels JJ, Berneman Z, Schroyens W, De Raeve H.

Acta Haematol. 2015;133(1):36-51. doi: 10.1159/000358580. Epub 2014 Aug 7. Review.

PMID:
25116092
7.

Splanchnic venous thrombosis driven by a constitutively activated JAK2 V617F philadelphia-negative myeloproliferative neoplasm: a case report.

Waiswa M, Seremba E, Ocama P, Ddungu H, Opio K, Okello C, O'shea T, Verhovsek M, Mutyabule R.

Afr Health Sci. 2014 Dec;14(4):1069-73. doi: 10.4314/ahs.v14i4.39.

8.

[The JAK2 mutation in myeloproliferative disorders: A predictive factor of thrombosis].

Mahjoub S, Baccouche H, Sahnoun M, Kaabi H, Manai Z, Slama H, Ben Romdhane N.

Tunis Med. 2015 Jul;93(7):474-7. French.

9.

Vascular events in Korean patients with myeloproliferative neoplasms and their relationship to JAK2 mutation.

Bang SM, Lee JS, Ahn JY, Lee JH, Hyun MS, Kim BS, Park MR, Chi HS, Kim HY, Kim HJ, Lee MH, Kim H, Won JH, Yoon HJ, Oh DY, Nam EM, Bae SH, Kim BK; Korean MPN Working Party.

Thromb Haemost. 2009 Mar;101(3):547-51.

PMID:
19277418
10.

Discrepancies between bone marrow histopathology and clinical phenotype in BCR-ABL1-negative myeloproliferative neoplasms associated with splanchnic vein thrombosis.

Gianelli U, Iurlo A, Cattaneo D, Bossi A, Cortinovis I, Augello C, Moro A, Savi F, Castelli R, Brambilla C, Bianchi P, Primignani M, Cortelezzi A, Bosari S.

Leuk Res. 2015 May;39(5):525-9. doi: 10.1016/j.leukres.2015.03.009. Epub 2015 Mar 19.

PMID:
25840747
11.

Incidence of the JAK2 V617F mutation among patients with splanchnic or cerebral venous thrombosis and without overt chronic myeloproliferative disorders.

De Stefano V, Fiorini A, Rossi E, Za T, Farina G, Chiusolo P, Sica S, Leone G.

J Thromb Haemost. 2007 Apr;5(4):708-14. Epub 2007 Jan 29.

12.

Outcome of patients with splanchnic venous thrombosis presenting without overt MPN: a role for the JAK2 V617F mutation re-evaluation.

Colaizzo D, Amitrano L, Guardascione MA, Tiscia GL, D'Andrea G, Longo VA, Grandone E, Margaglione M.

Thromb Res. 2013 Aug;132(2):e99-e104. doi: 10.1016/j.thromres.2013.07.014. Epub 2013 Aug 1.

PMID:
23916380
13.

The mutation profile of JAK2 and CALR in Chinese Han patients with Philadelphia chromosome-negative myeloproliferative neoplasms.

Wu Z, Zhang X, Xu X, Chen Y, Hu T, Kang Z, Li S, Wang H, Liu W, Ma X, Guan M.

J Hematol Oncol. 2014 Jul 15;7:48. doi: 10.1186/s13045-014-0048-6.

14.

The C allele of JAK2 rs4495487 is an additional candidate locus that contributes to myeloproliferative neoplasm predisposition in the Japanese population.

Ohyashiki JH, Yoneta M, Hisatomi H, Iwabuchi T, Umezu T, Ohyashiki K.

BMC Med Genet. 2012 Jan 17;13:6. doi: 10.1186/1471-2350-13-6.

15.

Identifying and addressing unmet clinical needs in Ph-neg classical myeloproliferative neoplasms: a consensus-based SIE, SIES, GITMO position paper.

Barosi G, Vannucchi AM, De Stefano V, Pane F, Passamonti F, Rambaldi A, Saglio G, Barbui T, Tura S.

Leuk Res. 2014 Feb;38(2):155-60. doi: 10.1016/j.leukres.2013.09.008. Epub 2013 Sep 19.

PMID:
24378116
16.

Genomic aberrations of myeloproliferative and myelodysplastic/myeloproliferative neoplasms in chronic phase and during disease progression.

Hahm C, Huh HJ, Mun YC, Seong CM, Chung WS, Huh J.

Int J Lab Hematol. 2015 Apr;37(2):181-9. doi: 10.1111/ijlh.12257. Epub 2014 May 21.

PMID:
24845343
18.

From Philadelphia-Negative to JAK2-Positive: Effect of Genetic Discovery on Risk Stratification and Management.

Pemmaraju N, Moliterno AR.

Am Soc Clin Oncol Educ Book. 2015:139-45. doi: 10.14694/EdBook_AM.2015.35.139. Review.

19.

Markers of myeloproliferative diseases in childhood polycythemia vera and essential thrombocythemia.

Teofili L, Giona F, Martini M, Cenci T, Guidi F, Torti L, Palumbo G, Amendola A, Foà R, Larocca LM.

J Clin Oncol. 2007 Mar 20;25(9):1048-53.

20.

Myeloproliferative neoplasms in Budd-Chiari syndrome and portal vein thrombosis: a meta-analysis.

Smalberg JH, Arends LR, Valla DC, Kiladjian JJ, Janssen HL, Leebeek FW.

Blood. 2012 Dec 13;120(25):4921-8. doi: 10.1182/blood-2011-09-376517. Epub 2012 Oct 4. Review.

Items per page

Supplemental Content

Write to the Help Desk